WO2001010434A1 - Pharmaceutical compositions containing n-palmitoylethanolamide and use thereof in the veterinary field - Google Patents
Pharmaceutical compositions containing n-palmitoylethanolamide and use thereof in the veterinary field Download PDFInfo
- Publication number
- WO2001010434A1 WO2001010434A1 PCT/IT1999/000259 IT9900259W WO0110434A1 WO 2001010434 A1 WO2001010434 A1 WO 2001010434A1 IT 9900259 W IT9900259 W IT 9900259W WO 0110434 A1 WO0110434 A1 WO 0110434A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- palmitoylethanolamide
- treatment
- micronized
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 208000003401 Eosinophilic Granuloma Diseases 0.000 claims abstract description 20
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 claims abstract description 20
- 241000282326 Felis catus Species 0.000 claims abstract description 15
- 229950007031 Palmidrol Drugs 0.000 claims abstract description 15
- 208000002260 Keloid Diseases 0.000 claims abstract description 13
- 210000001117 Keloid Anatomy 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 241000283073 Equus caballus Species 0.000 claims abstract description 7
- 241000282324 Felis Species 0.000 claims abstract description 6
- 230000003902 lesions Effects 0.000 claims description 12
- 230000001684 chronic Effects 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000001154 acute Effects 0.000 claims description 5
- 229940095353 Oral Granules Drugs 0.000 claims description 2
- 229940042126 Oral Powder Drugs 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 241000283086 Equidae Species 0.000 abstract description 15
- 230000002327 eosinophilic Effects 0.000 abstract description 6
- 210000003491 Skin Anatomy 0.000 abstract description 5
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 abstract description 3
- 210000002435 Tendons Anatomy 0.000 description 11
- 241000219843 Pisum Species 0.000 description 8
- 235000010582 Pisum sativum Nutrition 0.000 description 8
- 229920000120 polyethyl acrylate Polymers 0.000 description 8
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- 230000002860 competitive Effects 0.000 description 5
- 229940079593 drugs Drugs 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 241000777300 Congiopodidae Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 206010059837 Adhesion Diseases 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 3
- 229960001334 Corticosteroids Drugs 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 210000003414 Extremities Anatomy 0.000 description 3
- 235000019759 Maize starch Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010043255 Tendonitis Diseases 0.000 description 3
- 201000004384 alopecia Diseases 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 201000004624 dermatitis Diseases 0.000 description 3
- 231100000406 dermatitis Toxicity 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 201000004415 tendinitis Diseases 0.000 description 3
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010023330 Keloid scar Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002757 inflammatory Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000306 recurrent Effects 0.000 description 2
- 230000000472 traumatic Effects 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229960001631 Carbomer Drugs 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 240000002268 Citrus limon Species 0.000 description 1
- 210000000078 Claw Anatomy 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-α-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 229960001452 alpha-Tocopherol Acetate Drugs 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 150000001887 cortisones Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 230000036566 epidermal hyperplasia Effects 0.000 description 1
- 230000003628 erosive Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003176 fibrotic Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 201000010912 granulomatous dermatitis Diseases 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 231100000197 serious side effect Toxicity 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 231100000730 tolerability Toxicity 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99939603A EP1207870B1 (en) | 1999-08-06 | 1999-08-06 | Pharmaceutical compositions containing n-palmitoylethanolamide and use thereof in the veterinary field |
| AT99939603T AT290858T (de) | 1999-08-06 | 1999-08-06 | N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin |
| PCT/IT1999/000259 WO2001010434A1 (en) | 1999-08-06 | 1999-08-06 | Pharmaceutical compositions containing n-palmitoylethanolamide and use thereof in the veterinary field |
| DK99939603T DK1207870T3 (da) | 1999-08-06 | 1999-08-06 | Farmaceutiske præparater, der indeholder N-palmitoylethanolamid og anvendelse deraf |
| DE69924304T DE69924304T2 (de) | 1999-08-06 | 1999-08-06 | N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin |
| US10/030,060 US6548550B1 (en) | 1999-08-06 | 1999-08-06 | Pharmaceutical compositions containing N-palmitoylethanolamide and use thereof in the veterinary field |
| ES99939603T ES2239453T3 (es) | 1999-08-06 | 1999-08-06 | Composiciones farmaceuticas que contienen n-palmitoiletanolamida y uso de ellas en el campo veterinario. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IT1999/000259 WO2001010434A1 (en) | 1999-08-06 | 1999-08-06 | Pharmaceutical compositions containing n-palmitoylethanolamide and use thereof in the veterinary field |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2001010434A1 true WO2001010434A1 (en) | 2001-02-15 |
Family
ID=11333115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IT1999/000259 WO2001010434A1 (en) | 1999-08-06 | 1999-08-06 | Pharmaceutical compositions containing n-palmitoylethanolamide and use thereof in the veterinary field |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6548550B1 (und) |
| EP (1) | EP1207870B1 (und) |
| AT (1) | AT290858T (und) |
| DE (1) | DE69924304T2 (und) |
| DK (1) | DK1207870T3 (und) |
| ES (1) | ES2239453T3 (und) |
| WO (1) | WO2001010434A1 (und) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011027373A1 (en) * | 2009-09-07 | 2011-03-10 | Epitech Group S.R.L. | Composition containing ultra-micronized palmitoyl - ethanolamide |
| EP1406576B2 (en) † | 2001-07-18 | 2011-06-29 | Unilever PLC | Hair and/or scalp treatment compositions |
| WO2016146453A1 (en) | 2015-03-16 | 2016-09-22 | Vanderbilt Science Holding Ltd | Composition for use in the treatment of neuropathic pain |
| NL2017559B1 (en) * | 2016-09-30 | 2018-04-10 | Vanderbilt Science Holding Ltd | Method for preparing pulverized palmitoylethanolamide particles, particles obtainable by the method, and apharmaceutical or neutraceutical composition comprising saidparticles |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI250023B (en) * | 2001-10-22 | 2006-03-01 | Santen Pharma Co Ltd | Pharmaceutical composition for itch treating agent |
| CN101868222B (zh) * | 2007-12-06 | 2013-03-13 | 荷兰联合利华有限公司 | 个人护理组合物 |
| PT2444078T (pt) * | 2010-10-04 | 2017-11-15 | Epitech Group S P A | Utilização de amidas de ácidos mono e dicarboxílicos no tratamento de doenças renais |
| ITMI20131132A1 (it) | 2013-07-05 | 2015-01-06 | Epitech Group Srl | Uso in combinazione di amidi di acidi mono- e dicarbossilici e silimarina nel trattamento di patologie renali |
| EP2921167B1 (en) | 2014-03-19 | 2016-08-17 | EPITECH GROUP S.p.A. | Pharmaceutical composition comprising palmitoylethanolamide and l-acetylcarnitine |
| EP2944309B1 (en) | 2014-05-14 | 2019-03-20 | EPITECH GROUP S.p.A. | Use of palmitoylethanolamide in combination with opioids |
| HUE044801T2 (hu) | 2014-07-08 | 2019-11-28 | Epitech Group S P A | Adelmidrol alkalmazása epitheliális mûködési zavarok kezelésében |
| EP2985037B1 (en) | 2014-08-13 | 2017-06-21 | EPITECH GROUP S.p.A. | A pharmaceutical composition comprising palmitoylethanolamid and cytidine-diphosphocholine |
| WO2016183134A1 (en) * | 2015-05-12 | 2016-11-17 | Cutting Edge Medical Solutions, Llc | Palmitoylethanolamide compositions |
| IT202000007831A1 (it) | 2020-04-14 | 2021-10-14 | Epitech Group S P A | Adelmidrol per l’uso nel trattamento della fibrosi polmonare |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0550006A2 (en) * | 1991-12-31 | 1993-07-07 | LIFEGROUP S.p.A. | Use of N-acyl derivatives of aminoalcohols for the manufacture of a medicament for the treatment of pathologies involving mast cells |
| EP0550008A2 (en) * | 1991-12-31 | 1993-07-07 | LIFEGROUP S.p.A. | Use of N-acyl derivatives of aminoalcohols with polycarboxylic acids for the manufacture of a medicament for the treatment of pathologies relating to mast cells |
| WO1996018391A2 (en) * | 1994-12-14 | 1996-06-20 | Lifegroup S.P.A. | Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor |
| WO1997010712A1 (en) * | 1995-09-19 | 1997-03-27 | Margolin Solomon B | Inhibition of tumor necrosis factor alpha |
-
1999
- 1999-08-06 EP EP99939603A patent/EP1207870B1/en not_active Expired - Lifetime
- 1999-08-06 DK DK99939603T patent/DK1207870T3/da active
- 1999-08-06 AT AT99939603T patent/AT290858T/de unknown
- 1999-08-06 DE DE69924304T patent/DE69924304T2/de not_active Expired - Lifetime
- 1999-08-06 WO PCT/IT1999/000259 patent/WO2001010434A1/en active IP Right Grant
- 1999-08-06 US US10/030,060 patent/US6548550B1/en not_active Expired - Lifetime
- 1999-08-06 ES ES99939603T patent/ES2239453T3/es not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0550006A2 (en) * | 1991-12-31 | 1993-07-07 | LIFEGROUP S.p.A. | Use of N-acyl derivatives of aminoalcohols for the manufacture of a medicament for the treatment of pathologies involving mast cells |
| EP0550008A2 (en) * | 1991-12-31 | 1993-07-07 | LIFEGROUP S.p.A. | Use of N-acyl derivatives of aminoalcohols with polycarboxylic acids for the manufacture of a medicament for the treatment of pathologies relating to mast cells |
| WO1996018391A2 (en) * | 1994-12-14 | 1996-06-20 | Lifegroup S.P.A. | Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor |
| WO1997010712A1 (en) * | 1995-09-19 | 1997-03-27 | Margolin Solomon B | Inhibition of tumor necrosis factor alpha |
Non-Patent Citations (1)
| Title |
|---|
| MAZZARI S ET AL: "N-(2-HYDROXYETHYL)HEXADECANAMIDE IS ORALLY ACTIVE IN REDUCING EDEMA FORMATION AND INFLAMMATORY HYPERALGESIA BY DOWN-MODULATING MAST CELL ACTIVATION", EUROPEAN JOURNAL OF PHARMACOLOGY,NL,AMSTERDAM, vol. 300, no. 3, 1 January 1996 (1996-01-01), pages 227 - 236, XP000573451, ISSN: 0014-2999 * |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1406576B2 (en) † | 2001-07-18 | 2011-06-29 | Unilever PLC | Hair and/or scalp treatment compositions |
| US8663701B2 (en) | 2009-09-07 | 2014-03-04 | Epitech Group S.R.L. | Compositions containing ultra-micronized palmitoyl-ethanolamide |
| EP2475352B1 (en) | 2009-09-07 | 2015-06-17 | Epitech Group S.r.l. | Composition containing ultra-micronized palmitoyl - ethanolamide |
| KR20120093861A (ko) * | 2009-09-07 | 2012-08-23 | 에피테크 그룹 에스.알.엘. | 초미세화 팔미토일-에탄올아미드를 함유한 조성물 |
| JP2013503855A (ja) * | 2009-09-07 | 2013-02-04 | エピテック・グループ・エス．アール．エル． | 超微粉化パルミトイル−エタノールアミドを含む組成物 |
| US8470373B2 (en) | 2009-09-07 | 2013-06-25 | Epitech Group S.R.L. | Composition containing ultra-micronized palmitoyl-ethanolamide |
| WO2011027373A1 (en) * | 2009-09-07 | 2011-03-10 | Epitech Group S.R.L. | Composition containing ultra-micronized palmitoyl - ethanolamide |
| EP2796129A1 (en) * | 2009-09-07 | 2014-10-29 | Epitech Group S.r.l. | Composition containing ultra - micronized palmitoyl - ethanolamide |
| CN102186459A (zh) * | 2009-09-07 | 2011-09-14 | 晶源集团股份责任有限公司 | 含有超微粒化十六酰胺乙醇的组合物 |
| EP2796129B1 (en) | 2009-09-07 | 2015-06-17 | Epitech Group S.r.l. | Composition containing ultra - micronized palmitoyl - ethanolamide |
| AU2009352080B2 (en) * | 2009-09-07 | 2015-12-24 | Epitech Group S.P.A. | Composition containing ultra-micronized palmitoyl - ethanolamide |
| CN106138022A (zh) * | 2009-09-07 | 2016-11-23 | 晶源集团有限公司 | 含有超微粒化十六酰胺乙醇的组合物 |
| KR101662871B1 (ko) | 2009-09-07 | 2016-10-05 | 에피테크 그룹 에스.알.엘. | 초미세화 팔미토일-에탄올아미드를 함유한 조성물 |
| WO2016146453A1 (en) | 2015-03-16 | 2016-09-22 | Vanderbilt Science Holding Ltd | Composition for use in the treatment of neuropathic pain |
| NL2017559B1 (en) * | 2016-09-30 | 2018-04-10 | Vanderbilt Science Holding Ltd | Method for preparing pulverized palmitoylethanolamide particles, particles obtainable by the method, and apharmaceutical or neutraceutical composition comprising saidparticles |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1207870B1 (en) | 2005-03-16 |
| DE69924304T2 (de) | 2006-04-13 |
| ES2239453T3 (es) | 2005-09-16 |
| US6548550B1 (en) | 2003-04-15 |
| EP1207870A1 (en) | 2002-05-29 |
| AT290858T (de) | 2005-04-15 |
| DE69924304D1 (de) | 2005-04-21 |
| DK1207870T3 (da) | 2005-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6548550B1 (en) | Pharmaceutical compositions containing N-palmitoylethanolamide and use thereof in the veterinary field | |
| CA2762013C (en) | Granulation of pirfenidone and pharmaceutically acceptable excipients | |
| US5296476A (en) | Skin care compositions | |
| EP0098743B1 (en) | Phenyl alpha-acyloxyacetamide derivates and their therapeutic use | |
| EP0740938B1 (de) | Verwendung von Prolin als einziger therapeutischer Wirkstoff zur Herstellung eines Arzneimittels zur Behandlung von rheumatischen Erkrankungen und von chronischen und traumatisch bedingten Schmerzzuständen | |
| JP2002511860A (ja) | 皮膚の老化およびシワを治療および予防するためのイソフラボノイド | |
| WO1994009798A1 (en) | Mixtures or complexes containing calcium and sulfate | |
| JP4490035B2 (ja) | 疾患軽減製剤 | |
| EP0784975A1 (en) | Use of acetylsalicylic acid in the manufacture of a drug for the treatment of skin injuries | |
| WO1992002231A1 (fr) | Agent anti-vih | |
| DE2548367A1 (de) | Heilmittel und verfahren zu seiner herstellung | |
| JP2005194239A (ja) | セラミド合成促進剤及び皮膚外用剤 | |
| JP2563158B2 (ja) | ノナテトラエン酸誘導体 | |
| DE19815411A1 (de) | Thermogenese stimulierend wirksame Arzneimittel | |
| JPH10114665A (ja) | 津液改善剤及びそれを含有する経口投与用組成物 | |
| JP4421847B2 (ja) | 脂肪分解促進剤 | |
| JP2016210703A (ja) | 時計遺伝子発現促進用組成物 | |
| EP0161144B1 (fr) | Composition pharmaceutique destinée à une administration orale constituée d'une part, à titre de principe actif, par la 9-alpha,11-bêta-dichloro 16-alpha-méthyl 21-oxycarbonyldicyclohexylméthyloxy pregna-1,4-diène 3,20-dione et d'autre part, par un excipient pharmaceutique inerte apte à permettre l'action du produit dans le rectum ou le colon et utilisation dudit principe actif dans la fabrication d'une telle composition | |
| EP0492747B1 (en) | Pharmaceutical preparation for topical application | |
| JPH0948732A (ja) | 活性酸素消去剤及びそれを含む組成物 | |
| JPH10298055A (ja) | 抗アンドロゲン剤及び養毛剤，皮脂分泌抑制剤 | |
| JPH10114650A (ja) | 津液改善剤及びそれを含有する経口投与用組成物 | |
| JP2003026592A (ja) | 甘草発酵抽出物からなる抗アンドロゲン剤 | |
| DD249186A1 (de) | Herstellungsverfahren einer neuen glibenclamid-arzneiform mit hoher bioverfuegbarkeit | |
| JP3178763B2 (ja) | シムノールサルフェート製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1999939603 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10030060 Country of ref document: US |
|
| WWP | Wipo information: published in national office |
Ref document number: 1999939603 Country of ref document: EP |
|
| WWG | Wipo information: grant in national office |
Ref document number: 1999939603 Country of ref document: EP |